Clinical Scorecard: Association of Hepatitis B and C Viral Infections with Different Subtypes of B-cell Non-Hodgkin Lymphoma: Evidence Supporting Links to Splenic Marginal Zone Lymphoma

At a Glance

Key Highlights

• HBV infection prevalence is significantly higher in aggressive B-NHL and SMZL patients compared to the general population.
• HCV infection is significantly more prevalent in indolent B-NHL subtypes, with the highest rates observed in SMZL.
• This study is the first large-scale systematic evaluation showing a positive association of both HBV and HCV with specific B-NHL subtypes, especially SMZL.

Guideline-Based Recommendations

Diagnosis

• Screen B-NHL patients for HBV (HBs-Ag) and HCV (anti-HCV Ab) infections, particularly in HBV/HCV endemic areas.
• Classify B-NHL subtypes according to WHO criteria to identify those with higher viral infection prevalence such as SMZL.

Management

• Consider antiviral therapy targeting HCV in SMZL patients, as anti-HCV treatment has been associated with remission.
• Evaluate potential benefits of HBV-eradicating therapies in SMZL patients with HBV infection based on emerging evidence.

Monitoring & Follow-up

• Monitor viral serostatus in B-NHL patients during treatment to assess response and potential viral reactivation risks.
• Regularly assess lymphoma progression in patients with concurrent hepatitis virus infections.

Risks

• Increased risk of B-NHL, particularly SMZL, in patients with chronic HBV or HCV infection.
• Potential for viral reactivation during immunosuppressive lymphoma therapies necessitating vigilant monitoring.

Patient & Prescribing Data

Patients diagnosed with B-NHL subtypes, especially SMZL, in HBV and HCV endemic regions.

Antiviral therapy against HCV can induce remission in SMZL; emerging data suggest HBV eradication may also benefit HBV-positive SMZL patients.

Clinical Best Practices

• Systematically test all B-NHL patients for HBV and HCV infection status at diagnosis.
• Integrate viral infection status into lymphoma subtype risk stratification and management planning.
• Employ antiviral therapies in virus-associated B-NHL subtypes to improve outcomes.
• Maintain awareness of geographic and epidemiologic variability in viral prevalence when interpreting lymphoma risk.

References

• WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
• Epidemiological investigation of hepatitis viral infection in China
• Association of HCV with B-NHL subtypes including SMZL
• Reports of remission in SMZL with antiviral therapy
• Romanian study on HBV prevalence in SMZL